Interleukin-6 is responsible for aberrant B-cell receptor-mediated regulation of RAG expression in systemic lupus erythematosus

Immunology

Volumn 122, Issue 3, 2007, Pages 371-380

  Hillion, Sophie ^a   Garaud, Soizic ^a   Devauchelle, Valérie ^a   Bordron, Anne ^a   Berthou, Christian ^a   Youinou, Pierre ^a,b   Jamin, Christophe ^a  

^a FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

Author keywords

B cells; Cell activation; Interleukin 6; Recombination activating gene; Systemic lupus erythematosus

Indexed keywords

B LYMPHOCYTE RECEPTOR; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; RAG1 PROTEIN; RAG2 PROTEIN;

ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOPLASM; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

ANTIBODIES, ANTI-IDIOTYPIC; B-LYMPHOCYTE SUBSETS; CELLS, CULTURED; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; GENE REARRANGEMENT, B-LYMPHOCYTE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOGLOBULIN M; INTERLEUKIN-6; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 35048836608     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2007.02649.x     Document Type: Article

References (52)

1. Renaudineau Y, Pers JO, Bendaoud B, Jamin C, Youinou P. Dysfunctional B cells in systemic lupus erythematosus. Autoimmun Rev 2004 3 : 516 23.
2. Ferry H, Jones M, Vaux DJ, Roberts IS, Cornall RJ. The cellular location of self-antigen determines the positive and negative selection of autoreactive B cells. J Exp Med 2003 189 : 1415 25.
3. Jacobi AM, Diamond B. Balancing diversity and tolerance: lessons from patients with systemic lupus erythematosus. J Exp Med 2005 202 : 341 4.
4. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, Nussenzweig MC. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005 201 : 703 11.
5. Pugh-Bernard AE, Silverman GJ, Cappione AJ, Villano ME, Ryan DH, Insel RA, Sanz I. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J Clin Invest 2001 108 : 1061 70.
6. Cappione A, Anolik JH, Pugh-Bernard A, Barnard J, Dutcher P, Silverman G, Sanz I. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest 2005 115 : 3205 16.
7. Wakeland EK, Liu K, Graham RR, Behrens TW. Delineating the genetic basis of systemic lupus erythematosus. Immunity 2001 15 : 397 408.
8. Rice JS, Newman J, Wang C, Michael DJ, Diamond B. Receptor editing in peripheral B cell tolerance. Proc Natl Acad Sci USA 2005 102 : 1608 13.
9. Sekiguchi DR, Eisenberg RA, Weigert M. Secondary heavy chain rearrangement: a mechanism for generating anti-double-stranded DNA B cells. J Exp Med 2003 197 : 27 39.
10. Edry E, Melamed D. Receptor editing in positive and negative selection of B lymphopoiesis. J Immunol 2004 173 : 4265 71.
11. Girschick HJ, Grammer AC, Nanki T, Vazquez E, Lipsky PE. Expression of recombination-activating genes 1 and 2 in peripheral B cells of patients with systemic lupus erythematosus. Arthritis Rheum 2002 46 : 1255 63.
12. Monestier M, Zouali M. Receptor revision and systemic lupus erythematosus. Scand J Immunol 2002 55 : 425 31.
13. Lee J, Desiderio S. Cyclin A/CDK2 regulates V(D)J recombination by coordinating RAG-2 accumulation and DNA repair. Immunity 1999 11 : 771 81.
14. Mizuta R, Mizuta M, Araki S, Kitamura D. RAG2 is down-regulated by cytoplasmic sequestration and ubiquitin-dependent degradation. J Biol Chem 2002 277 : 41423 7.
15. Jiang H, Chang FC, Ross AE, Lee J, Nakayama K, Desiderio S. Ubiquitylation of RAG-2 by Skp2-SCF links destruction of the V(D)J recombinase to the cell cycle. Mol Cell 2005 18 : 699 709.
16. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004 18 : 2699 711.
17. + cells of older lupus mice. Eur J Immunol 1997 27 : 1901 10.
18. Meffre E, Papavasiliou F, Cohen P et al. Antigen receptor engagement turns off the V(D)J recombination machinery in human tonsil B cells. J Exp Med 1998 188 : 765 72.
19. Hertz M, Kouskoff V, Nakamura T, Nemazee D. V(D)J recombinase induction in splenic B lymphocytes is inhibited by antigen-receptor signalling. Nature 1998 394 : 292 5.
20. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982 25 : 1271 7.
21. Hillion S, Saraux A, Youinou P, Jamin C. Expression of RAGs in peripheral B cells outside germinal centers is associated with the expression of CD5. J Immunol 2005 174 : 5553 61.
22. Gartner F, Alt FW, Monroe RJ, Seidl KJ. Antigen-independent appearance of recombination activating gene (RAG)-positive bone marrow B cells in the spleens of immunized mice. J Exp Med 2000 192 : 1745 54.
23. YuW, Nagaoka H, Jankovic M et al. Continued RAG expression in late stages of B cell development and no apparent re-induction after immunization. Nature 1999 400 : 682 7.
24. low B cell population in the peripheral blood of patients with SLE. Clin Immunol 2004 113 : 161 71.
25. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood 2005 105 : 4390 8.
26. Oettinger MA, Schatz DG, Gorka C, Baltimore D. RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. Science 1990 248 : 1517 23.
27. Pers JO, Jamin C, Le Corre R, Lydyard PM, Youinou P. Ligation of CD5 on resting B cells, but not on resting T cells, results in apoptosis. Eur J Immunol 1998 28 : 4170 6.
28. Ghia P, Gratwohl A, Signer E, Winkler TH, Melchers F, Rolink AG. Immature B cells from human and mouse bone marrow can change their surface light chain expression. Eur J Immunol 1995 25 : 3108 14.
29. Solvason N, Wu WW, Kabra N, Wu X, Lees E, Howard MC. Induction of cell cycle regulatory proteins in anti-immunoglobulin-stimulated mature B lymphocytes. J Exp Med 1996 184 : 407 17.
30. Kip1, a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun 1999 257 : 609 14.
31. Robak E, Sysa-Jedrzejowska A, Stepien H, Robak T. Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus. Eur Cytokine Netw 1997 8 : 281 6.
32. Gagro A, McCloskey N, Challa A, Holder M, Grafton G, Pound JD, Gordon J. CD5-positive and CD5-negative human B cells converge to an indistinguishable population on signalling through B-cell receptors and CD40. Immunology 2000 101 : 201 9.
33. Morbach H, Singh SK, Faber C, Lipsky PE, Girschick HJ. Analysis of RAG expression by peripheral blood CD5+ and CD5- B cells of patients with childhood systemic lupus erythematosus. Ann Rheum Dis 2006 65 : 482 7.
34. Suzuki N, Harada T, Mihara S, Sakane T. Characterization of a germline Vk gene encoding cationic anti-DNA antibody and role of receptor editing for development of the autoantibody in patients with systemic lupus erythematosus. J Clin Invest 1996 98 : 1843 50.
35. Dorner T, Foster SJ, Farner NL, Lipsky PE. Immunoglobulin kappa chain receptor editing in systemic lupus erythematosus. J Clin Invest 1998 102 : 688 94.
36. Dorner T, Farner NL, Lipsky PE. Ig lambda and heavy chain gene usage in early untreated systemic lupus erythematosus suggests intensive B cell stimulation. J Immunol 1999 163 : 1027 36.
37. Hansen A, Dorner T, Lipsky PE. Use of immunoglobulin variable-region genes by normal subjects and patients with systemic lupus erythematosus. Int Arch Allergy Immunol 2000 123 : 36 45.
38. Dorner T, Lipsky PE. Immunoglobulin variable-region gene usage in systemic autoimmune diseases. Arthritis Rheum 2001 44 : 2715 27.
39. Potter KN, Mockridge CI, Rahman A. Disturbances in peripheral blood B cell subpopulations in autoimmune patients. Lupus 2002 11 : 872 7.
40. Casellas R, Zhang Q, Zheng NY, Mathias MD, Smith K, Wilson PC. Igkappa allelic inclusion is a consequence of receptor editing. J Exp Med 2007 204 : 153 60.
41. Kip1 is down-regulated by two different mechanisms in human lymphoid cells undergoing apoptosis. Oncogene 2000 19 : 3115 20.
42. Banerji L, Glassford J, Lea NC, Thomas NS, Klaus GG, Lam EW. BCR signals target p27 (Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells. Oncogene 2001 20 : 7352 67.
43. Llorian M, Stamataki Z, Hill S, Turner M, Martensson IL. The PI3K p110delta is required for down-regulation of RAG expression in immature B cells. J Immunol 2007 178 : 1981 5.
44. Kitani A, Hara M, Hirose T et al. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin Exp Immunol 1992 88 : 75 83.
45. Kip1 degradation in HepG2 cells. Oncogene 2000 19 : 3675 83.
46. Nagafuchi H, Suzuki N, Mizushima Y, Sakane T. Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus. J Immunol 1993 151 : 6525 34.
47. Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, Kishimoto T. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988 167 : 332 44.
48. Kopf M, Baumann H, Freer G et al. Impaired immune and acute-phase responses in IL-6-deficient mice. Nature 1994 368 : 339 42.
49. Sasai M, Saeki Y, Ohshima S et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum 1999 42 : 1635 43.
50. Stuart RA, Littlewood AJ, Maddison PJ, Hall ND. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol 1995 13 : 17 22.
51. Liu K, Liang C, Liang Z, Tus K, Wakeland EK. Sle1ab mediates the aberrant activation of STAT3 and Ras-ERK signaling pathways in B lymphocytes. J Immunol 2005 174 : 1630 7.
52. Llorente L, Zou W, Levy Y et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995 181 : 839 44.